First, we evaluated the performance of the delivery system by using AD as an evaluation model and beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1)37 as a target to explore whether the systemic delivery of siRNA could elicit pharmacologic effects. Here, BACE1 is linked to Alzheimer disease.